We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Courtney DiNardo

Courtney DiNardo MD

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas

Dr. DiNardo is an academic clinical researcher with a primary focus on individualized therapy and precision oncology for myeloid malignancies, including the optimal incorporation of genomics into standard risk assessments and treatment algorithms, and the clinical evaluation of targeted therapeutics for molecularly-defined patient subgroups. Dr. DiNardo has 7 years of experience in designing, overseeing, and executing successful clinical trials; from Phase 1 dose-finding studies to innovative investigator-initiated Phase II trials, to serving as the international lead of confirmatory randomized Phase III trials. Dr. DiNardo has served an integral role in several highly influential trials involving IDH1, IDH2 and BCL2 inhibitors, which have led to the FDA approval of three therapies in AML since 2017 (the first-in-class IDH2 inhibitor enasidenib, the IDH1 inhibitor ivosidenib, and the BCL2 inhibitor venetoclax in combination with hypomethylating agents).

Disclosures

Dr. DiNardo has an advisory/consulting role for Abbvie, Agios, Celgene, Daiichi-Sankyo, and Notable Labs.